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Vascular endothelial growth factor-B (VEGFB) is an angiogenic and neuroprotective protein that reduces hypoxic and ischemic neuronal
injury. To determine if VEGFB also regulates neurogenesis in the adult brain, we studied the effects of VEGFB administration in vitro and in vivo,
as well as the effect of VEGFB gene knockout (KO) in mice, on bromodeoxyuridine (BrdU) incorporation and expression of immature neuronal
markers in the subgranular zone (SGZ) of the hippocampal dentate gyrus and the forebrain subventricular zone (SVZ). Intracerebroventricular
VEGFB administration increased BrdU incorporation into cells of neuronal lineage both in vitro and in vivo, and VEGFB-KO mice showed
impaired neurogenesis, consistent with a neurogenesis-promoting effect of VEGFB. In addition, intraventricular administration of VEGFB
restored neurogenesis to wild-type levels in VEGFB-KO mice. These results suggest a role for VEGFB in the regulation of adult neurogenesis,
which could have therapeutic implications for diseases associated with central neuronal loss.
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Members of the vascular endothelial growth factor (VEGF)
family of proteins were identified based on their angiogenic
and vessel permeability-inducing properties (Keck et al., 1989;
Leung et al., 1989) and were subsequently found to couple
hypoxia to angiogenesis in a wide range of tissues (Shweiki et
al., 1992). The prototypical VEGF, VEGFA, also exerts direct,
survival-promoting effects on nonvascular cells, including
hematopoietic cells (Gerber et al., 2002), cardiomyocytes
(Giordano et al., 2001), renal tubular epithelial cells (Kanellis
et al., 2000), and neurons (Jin et al., 2000b). For example,
VEGFA administration has neuroprotective effects in animal
models of stroke (Hayashi et al., 1998; Sun et al., 2003; Zhang
et al., 2000) and motor neuron disease (Azzouz et al., 2004;
Lambrechts et al., 2003; Sopher et al., 2004). VEGFA also
stimulates neurogenesis, or the production of new neurons, in
the adult brain (Jin et al., 2002b; Louissaint et al., 2002), and
this may be a key feature of the vascular niche (Palmer et al.,0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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brain regions. VEGFA acts through two receptor tyrosine
kinases, VEGFR1 and VEGFR2, and also interacts with co-
receptor neuropilins that may function in ligand presentation,
but most known effects of VEGFA have been ascribed to
VEGFR2 (Neufeld et al., 1999).
VEGFB is an angiogenic growth factor (Silvestre et al.,
2003) with 88% amino acid sequence homology to VEGFA
(Olofsson et al., 1996) and selective affinity for VEGFR1
(Olofsson et al., 1998). VEGFB-knockout (KO) mice show
abnormalities of cardiac development and function (Aase et al.,
2001; Bellomo et al., 2000) and hypoxia-induced remodeling
of the pulmonary vasculature (Wanstall et al., 2002), but no
change in the expression of VEGFA or VEGF receptors, or in
VEGFA-induced angiogenesis (Aase et al., 2001). VEGFB is
also expressed in the brain, where it is induced by brain injury
(Nag et al., 2002). We reported recently that VEGFB-KO mice
exhibit increased infarct size and more severe neurological
deficits following stroke induced by occlusion of the middle
cerebral artery (Sun et al., 2004), consistent with a neuropro-
tective function of VEGFB. VEGFB also reduced hypoxic
death of cultured cerebral cortical neurons in vitro (Sun et al.,
2004), suggesting that its protective effect may involve a direct89 (2006) 329 – 335
www.e
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and neurogenesis-promoting effects identified previously for
VEGFA, we investigated the possibility that VEGFB might
also regulate neurogenesis, using the VEGFB-KO mice
referred to above.
Methods
Cell culture
Primary cultures enriched in cells of neuronal lineage (75% hIII-tubulin and
82% Hu-immunopositive) were prepared from wild-type (WT) 15-day Charles
River CD1 mouse embryos. Cell suspensions were plated at 2.0  105 cells/
cm2 on 24- or 96-well poly-d-lysine-coated plastic tissue culture dishes in
defined medium Neurobasal/B27 (Life Technologies, Inc., Rockville, MD)
containing 2 mM glutamine, 25 U/ml penicillin, and 25 Ag/ml streptomycin.
Cultures were kept in a humidified, 5% CO2 incubator at 37-C for 4 days, and
then maintained for an additional 2 days in the absence or presence of VEGFB
(10–100 ng/ml; R&D Systems Inc., Minneapolis, MN). This duration of
exposure to VEGFB was chosen to achieve a maximal, time-dependent effect.
BrdU (50 Ag/ml; Sigma, St. Louis, MO) was added for the final 24 hr, after
which BrdU incorporation was measured using a commercially available
ELISA kit (Roche, Indianapolis, IN) and cell proliferation was measured with
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Jin et
al., 2002a).
BrdU and cell-type marker proteins in neuronal cultures were localized by
dual-label immunocytochemistry using mouse monoclonal anti-BrdU (Roche,
Indianapolis, IN; 1:200), mouse monoclonal anti-nestin (Santa Cruz Biotech-
nology, Santa Cruz, CA; 1:100), and mouse monoclonal anti-NeuN (Chemicon;
1:200) as primary antibodies and FITC- and rhodamine-conjugated secondary
antibodies (Jackson Immuno-Research Laboratories, Inc.; 1:200). Controls
included preabsorbing the primary antibody and omitting the secondary
antibody. A Nikon PCM-2000 laser-scanning confocal microscope and Simple
PCI imaging software (Compix, Cranberry Township, PA) were used for
visualization.
VEGFB-knockout mice
Animal experiments were approved by local committee review and
conducted according to NIH guidelines. VEGFB-KO mice (Bellomo et al.,
2000) were obtained from Jackson Laboratories (Bar Harbor, ME), bred in
house, and genotyped by polymerase chain reaction using tail-tip genomic
DNA (Sun et al., 2004). Mice were used at 10–12 weeks of age.
RNA and protein measurements
To compare VEGFA, VEGFR1, and VEGFR2 mRNA expression in WT
and VEGFB-KO mice, total RNA was isolated and RT-PCR was performed
using a standard protocol and the following primers: VEGF-A sense,
CTGACATGAAGGAAGAGGAG; VEGF-A antisense, GTGTCTACAG-
GAATCCCAGA; VEGFR1 sense, AAGATTACATCCCCCTCAAT; VEGFR1
antisense, GAGCTTCCAGAATGAAAATG; VEGFR2 sense, GTAAAAGCA-
GGGAGTCTGTG; VEGFR2 antisense, GTGGTGGAAAGAACAACACT.
PCR products (VEGFA, 189bp; VEGFR1, 124bp; VEGFR2, 275bp) were
detected on 2% agarose gels, and their optical density was measured using
Scion imaging software.
For Western blotting, protein was extracted from mouse brain and 100 Ag
per lane was electrophoresed on 12% SDS-PAGE and transferred to
polyvinyldifluoridine membranes. Membranes were blocked with 5% nonfat
dried milk in PBS/0.1% Tween 20 and incubated overnight with goat
polyclonal anti-VEGFB (R&D, Minneapolis, MN; 1:100), rabbit polyclonal
anti-VEGFR1 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:500), or mouse
monoclonal anti-VEGFR2 (Santa Cruz Biotechnology, Santa Cruz, CA; 1:500).
Blots were washed with PBS/0.1% Tween-20 and incubated at room
temperature for 60 min with horseradish peroxidase-conjugated secondary
antibody (Santa Cruz Biotechnology; 1:2000). Peroxidase activity wasvisualized with a chemoluminescence substrate (NEN, Boston, MA) and
quantified by computerized densitometry.
BrdU administration
BrdU (50 mg/kg in saline i.p.) was given twice daily for 3 days and WT and
VEGFB-KO mice were killed 3 days or 2 weeks later. Mice were perfused with
0.9% saline followed by 4% paraformaldehyde in phosphate-buffered saline
(pH 7.4).
Immunohistochemistry
For single-label immunohistochemistry, 50 Am sections were cut with a
cryostat and stored at 80-C. Sections for BrdU immunohistochemistry
were treated with 2 M HCl at 37-C for 30 min and rinsed in 0.1 M boric
acid (pH 8.5) at room temperature for 10 min. Sections were incubated in
blocking solution (2% goat serum/0.3% Triton X-100/0.1% bovine serum
albumin in phosphate-buffered saline) for 30 min at room temperature, and
with mouse monoclonal anti-BrdU (Roche Applied Science, 1:200) or goat
polyclonal anti-DCX (Santa Cruz Biotechnology, Santa Cruz, CA; 1:100) at
4-C overnight. Sections were washed with phosphate-buffered saline,
incubated with biotinylated goat-anti-mouse secondary antibody (Vector
Laboratories, 1:200) for 1 h at 25-C, washed, and placed in avidin–
peroxidase conjugate (Vector Laboratories) solution for 1 h. The horseradish
peroxidase reaction was detected with 0.05% diaminobenzidine and 0.03%
H2O2. Processing was stopped with H2O and sections were dehydrated
through graded alcohols, cleared in xylene, and coverslipped in permanent
mounting medium (Vector Laboratories). Sections were examined with a
Nikon E300 epifluorescence microscope. For double-label immunohisto-
chemistry, paraffin-embedded, 6-Am sections were deparaffinized with xylene
and rehydrated with ethanol. The same BrdU and DCX primary antibodies
mentioned above were used, as well as FITC- and rhodamine-conjugated
secondary antibodies (Jackson Immuno-Research Laboratories, Inc.; 1:200).
Fluorescence signals were detected by Nikon PCM-2000 laser-scanning
confocal microscopy. Controls included omitting primary or secondary
antibody.
Cell counting
BrdU- or DCX-immunopositive cells were counted blindly in six
diaminobenzidine-stained, 50 Am coronal sections per animal, spaced 200
Am apart. Cells were counted under high-power (200) on a Nikon E300
microscope with a Magnifire digital camera, and the image was displayed on a
computer monitor. Results were expressed as the average number of BrdU-
positive cells per section.
Klenow staining
To evaluate the possibility that VEGFB increases the number of BrdU-
labeled cells by reducing cell death rather than increasing proliferation,
damaged cells containing DNA strand breaks were detected using the Klenow
fragment of DNA polymerase I, as described (Jin et al., 1999).
Intracerebroventricular administration of VEGFB in vivo
Wild-type or VEGFB-KO mice and adult male Sprague–Dawley rats were
anesthetized with 4% isoflurane in 70% N2O/30% O2 and implanted with
osmotic minipumps (Alzet 1003D; Alza Corporation, Mountain View,
California, USA). The cannula was placed in the right lateral ventricle, 2.0
(mice) or 3.8 mm (rats) deep to the pial surface, 0.82 (mice) or 0.6 mm
(rats) anteroposterior relative to bregma, and 1.5 (mice) or 1.3 mm (rats) lateral
to the midline. VEGFB (10 Ag/ml) or artificial cerebrospinal fluid (aCSF)
vehicle (128 mM NaCl, 2.5 mM KCl, 0.95 mM CaCl2, and 1.99 mM MgCl2)
was infused by the intracerebroventricular route at 1 Al/h for 3 days. BrdU (50
mg/kg i.p. in saline) was given twice daily for 3 days and animals were killed 3
days to 2 weeks later. Immunohistochemistry and cell counting were performed
as described above.
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The statistical significance of differences between means was evaluated by
Student’s t test for single comparisons and by ANOVA followed by post hoc t
tests for multiple comparisons, with P < 0.05 considered significant.
Results
Addition of VEGFB to cerebral cortical cultures produced
concentration-dependent enhancement of BrdU incorporation,
which increased by¨30% in the presence of 100 ng/ml VEGFB
(Fig. 1A). Immunocytochemistry showed that BrdU labeling
was associated with cells that expressed markers of immature
(e.g., nestin) but not mature (e.g., NeuN) cells of neuronal
lineage (Fig. 1B). This is consistent with our prior finding that
only ¨2% of cells in these cultures are of nonneuronal (glial or
endothelial) lineage (Jin et al., 2002a). Metabolic activity in
cultures, measured by the reduction of MTT, increased by
¨25% over the same range of VEGFB concentrations (Fig. 1C),
consistent with an increase in cell number.
As reported previously (Sun et al., 2004), VEGFB-KO mice
lacked VEGFB immunoreactivity in cerebral neurons and
vasculature, but were phenotypically indistinguishable from
WT mice under normal conditions during life. VEGFB-KO
mice showed no secondary decreases in VEGFA or VEGF
receptor RNA or protein expression that might lead one to
misattribute the effects of such changes to deletion of VEGFB
(Figs. 2A–B; note that VEGFR1 expression in brain is
undetectable by Western blot under basal conditions, but
becomes apparent after injury; Jin et al., 2000c).Fig. 1. VEGFB stimulates BrdU incorporation in murine cortical cultures in
vitro. Cultures enriched in neuronal precursors were treated with the indicated
concentrations of VEGFB for 48 h. BrdU (50 Ag/ml) was added, where
indicated, for the last 24 h of VEGF exposure. BrdU incorporation (A) and
MTT absorbance, an index of cell number, (B) were measured and expressed in
relation to control (0 ng/ml VEGFB) values. BrdU immunoreactivity was co-
localized with expression of the neuroepithelial precursor cell marker nestin
(C), but not with the mature neuronal marker NeuN (D). Data are mean values T
SEM from at least 3 cell cultures per concentration of VEGFB (A, B) or
representative fields (C, D). *P < 0.05 compared to 0 ng/ml VEGFB.After administration of BrdU, VEGFB-KO mice showed
reduced BrdU immunolabeling in the two major neuropro-
liferative brain regions—the subgranular zone (SGZ) of the
hippocampal dentate gyrus and the forebrain subventricular
zone (SVZ) (Fig. 2C). Counting of BrdU-immunopositive
cells in brain sections showed significantly reduced cell
counts in SGZ and SVZ of VEGFB-KO mice (Fig. 2D).
Intraventricular administration of VEGFB to VEGFB-KO
mice restored BrdU labeling to wild-type levels in both SGZ
and SVZ, which argues that the absence of VEGFB is
sufficient to explain impaired neurogenesis in VEGF-KO
mice.
BrdU immunoreactivity in SGZ and SVZ was associated
for the most part with expression of the immature neuronal
marker DCX (Fig. 2E), indicative of a neuronal lineage for
BrdU-labeled cells in SGZ and SVZ. In line with this
observation, DCX immunolabeling in SVZ of VEGFB-KO
mice was decreased to the same (¨30%) extent as was BrdU
labeling at 3 days after BrdU administration (Figs. 2F–G).
Reduced BrdU-immunopositive cell counts in VEGFB-KO
mice could, in principle, result not only from impaired
proliferation, but also from enhanced cell death. To evaluate
this possibility, we used Klenow labeling to detect CA1 cells
with DNA strand breaks in SGZ from WT and VEGFB-KO
mice (Jin et al., 1999). Fig. 3 shows that whereas Klenow
labeling was prominent in CA1 from mice subjected to
global cerebral ischemia (positive control), it was rare in
SGZ from both WT and VEGFB-KO mice. Consequently, it
is difficult to ascribe decreased BrdU labeling in VEGFB-
KO mice to increased cell damage leading to death.
If neurogenesis is decreased in the absence of VEGFB
expression, then the administration of exogenous VEGFB to
normal animals might stimulate neurogenesis. To test this
possibility, VEGFB or aCSF vehicle was infused into the
cerebral ventricles of rats given BrdU over the same 3-day
period, and brain sections were stained for BrdU and for DCX
at 3 days and 2 weeks after completing these treatments. Figs.
4A–B shows that VEGFB infusion increased BrdU labeling in
SGZ at 2 weeks and in SVZ at both 3 days and 2 weeks after
BrdU administration, reproducing in reverse the effects of
VEGFB gene knockout in mice. Again, BrdU labeling in these
regions was associated primarily with DCX-expressing, neu-
ronal cells (Figs. 4C–E).
Discussion
The principal finding we report here is that VEGFB
stimulates neurogenesis in the adult brain. The evidence for
this is that neurogenesis, demonstrated by BrdU labeling and
confirmed by immunohistochemical detection of co-expressed
neuronal lineage markers, is reduced in VEGFB-knockout mice
and enhanced in VEGB-treated neuronal cultures and in rats
given VEGFB by intraventricular injection. VEGFB, therefore,
joins a growing list of growth factors that can regulate the
production of new neurons in the brain, including the better-
characterized VEGF homolog VEGFA (Jin et al., 2002b;
Louissaint et al., 2002; Sun et al., 2003).
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induced neurogenesis? VEGFA and VEGFB act through
overlapping but nonidentical signaling systems—VEGFA
activates both VEGFR1 and VEGFR2 receptor tyrosine
kinases, whereas the effects of VEGFB are mediated by
VEGFR1 alone; both VEGFA and VEGFB can also bind to
neuropilin co-receptors (Matsumoto and Claesson-Welsh,Fig. 3. VEGFB deletion is not associated with increased cell death in SGZ.
Klenow labeling of cells with DNA strand breaks (pink), which was prominent
in the rat hippocampal CA1 region 72 h after transient (15 min) global cerebral
ischemia (top; positive control), was detected only rarely in SGZ (lower cell
layer of dentate gyrus, DG) of WT mice (bottom left) and was not increased in
VEGFB-KO mice (bottom right). Nuclei are stained with DAPI (blue). Data are
representative fields from 3 rats or 6 mice per condition.
Fig. 2. BrdU incorporation into SGZ and SVZ is reduced in VEGFB-KO mice
BrdU was given i.p. for 3 days and then localized by immunohistochemistry in
SGZ and SVZ. (A) Western blots of VEGFA, VEGFR1, and VEGFR2 protein
expression in brain of wild-type (WT) and VEGFB-KO mice, and densitometry
from three blots per protein, showing the ratio of optical densities in VEGFB
KO versus WT mice (mean T SEM, *P < 0.05 compared to WT). (B) PCR o
VEGFA, VEGFR1, and VEGFR2 mRNA expression in brain of wild-type (WT
and VEGFB-KO mice, and densitometry from three blots per mRNA, showing
the ratio of optical densities in VEGFB-KO versusWTmice (mean T SEM, *P <
0.05 compared to WT). (C) BrdU-immunopositive cell counts showed reduced
labeling (D) in SGZ and SVZ of VEGFB-KO mice (c), and restoration of WT
levels in KO mice given intracerebroventricular VEGFB (v). BrdU immuno
reactivity was co-localized with expression of the immature neuronal marke
DCX in SGZ and SVZ of VEGFB-KO mice (E). SVZ of VEGFB-KO mice also
showed reduced immunohistochemical expression of DCX (F, G). Data are
representative fields (C, E, F) or mean values T SEM (D, G) from 6 mice pe
condition. *P < 0.05 compared to control.2001). VEGFA binds to VEGFR1 with higher affinity than to
VEGFR2, but the interaction with VEGFR2 elicits a greater
increase in protein kinase activity, and the cytoproliferative
activity of VEGFA appears to be attributable primarily to its
effect on VEGFR2 (Ferrara et al., 2003). The extent to which
VEGFA and VEGFB increase neurogenesis also differs. Thus,
whereas both VEGFA (Jin et al., 2002b) and VEGFB (Fig. 1)
increased BrdU labeling and cell number by 20–30% in vitro,
VEGFA increased in vivo BrdU labeling in DG by ¨600% and
in SVZ by ¨270% (Sun et al., 2003), while VEGFB-induced
increases were only ¨50% in both regions (Fig. 4). Conse-
quently, the manner in which VEGFA and VEGFB promote
proliferation and survival of neuronal precursors is likely to
differ. The observation that neurogenesis is decreased in
VEGFB-KO mice provides further evidence for nonidentical
effects of the two VEGF isoforms..
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production of neurons is not surprising, in that VEGFB has
mitogenic effects on hematopoietic cells (Casella et al., 2003),
and some hematopoietic growth factors, including stem cell
factor (Casella et al., 2003) and erythropoietin (Shingo et al.,
2001), also promote neurogenesis. Other (e.g., angiogenic)
effects of VEGFB involve activation of Akt (Silvestre et al.,
2003), which has been implicated in neuronal effects ofFig. 4. VEGFB administration increases BrdU incorporation into SGZ and SVZ
of adult rats. VEGFB was given by the intraventricular and BrdU by the
intraperitoneal route for 3 days. VEGFB increased BrdU labeling in SGZ (A)
and SVZ (B). BrdU labeling co-localized with DCX expression in some but not
all BrdU-labeled cells, as seen at low magnification in both SGZ and SVZ of
control rats (C); in upper panel, arrows indicate BrdU-positive nuclei, asterisks
Dcx-positive cell bodies, and arrowheads dual-labeled cells; in lower panel, v
indicates lateral ventricle. Co-localization of BrdU and Dcx in SGZ and SVZ of
VEGFB-treated rats is seen at higher magnification in panel D. VEGFB
treatment also increased the percentage of BrdU-labeled cells that expressed
Dcx (E), which is consistent with, but not necessarily indicative of, a
stimulatory effect on neuronal differentiation, as well as on cell proliferation.
Data are mean values T SEM (A, B, E) or representative fields (C, D) from 6
rats per condition. The percentage of BrdU-positive cells that expressed Dcx
was increased after VEGFB administration, from ¨50% to ¨90% in DG, and
from ¨50% to ¨75% in SVZ. *P < 0.05, **P < 0.01 compared to no VEGFB
administration (CON).VEGFA (Jin et al., 2000a). VEGFB-induced angiogenesis is
associated with increased production of NO by endothelial NO
synthase (Silvestre et al., 2003), and alterations in NO
synthesis have been implicated in neurogenesis (Zhang et al.,
2001). VEGFA-induced neurogenesis in vitro is inhibited by
the VEGFR2 inhibitors SU1498 and oxindole I, the phospho-
lipase C inhibitor U73122, the protein kinase C inhibitor
GF102390X, the phosphatidylinositol 3-kinase inhibitor wort-
mannin, and the extracellular signal-related kinase kinase
inhibitor PD98059 (Jin et al., 2002b; Zhu et al., 2003). The
signaling pathways through which the interaction of VEGFB
with VEGFR-1 also promotes neurogenesis will be important
to investigate in future studies.
Adult neurogenesis may represent a mechanism for
responding to and mitigating brain injury. One respect in
which VEGFA and VEGFB differ is that only the former
appears to be inducible by hypoxia (Enholm et al., 1997), and
hypoxia-inducible VEGFA production could help couple brain
injuries, such as ischemia, to enhanced neurogenesis. Whether
cerebral ischemia induces VEGFB is uncertain, but VEGFB
expression was increased by traumatic thermal injury (Nag et
al., 2002), and could therefore be affected by other pathological
processes as well.
Two questions that are raised but cannot be answered by
this study are why there appears to be so much redundancy in
the ability of growth factors to stimulate neurogenesis and
what functional significance, if any, to attach to this
phenomenon. The apparent redundancy may reflect incom-
plete understanding of the complexity of neurogenesis
signaling. For example, different growth factors may be
induced by different physiological or pathological events (as
in the disparate effects of hypoxia on VEGFA and VEGFB),
act on different subpopulations of neuronal precursor cells, or
promote different stages of neurogenesis (e.g., proliferation,
survival, differentiation, or migration). The ability to demon-
strate defects on neurogenesis resulting from growth factor
gene-knockout, as reported for fibroblast growth factor-2
(Yoshimura et al., 2001), leukemia inhibitory factor (Bauer et
al., 2003), and now VEGFB, indicates that what redundancy
may exist in the regulation of neurogenesis is incomplete. The
functional significance of VEGFB-induced or other forms of
Y. Sun et al. / Developmental Biology 289 (2006) 329–335334adult neurogenesis is difficult to establish. Nevertheless,
current data indicate that neurons born in the adult brain
have the capacity to become functional (Carleton et al., 2003;
Jessberger and Kempermann, 2003; Song et al., 2002; van
Praag et al., 2002), and that inhibiting neurogenesis has
functional consequences as well (Raber et al., 2004). It is,
therefore, reasonable to hypothesize that VEGFB may
exercise distinctive effects on adult neurogenesis, and that
these effects could have therapeutic application in efforts to
replace cerebral neurons that die as a result of brain injury or
disease.
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